A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

J. Main, J. L. Brown, C. Howells, R. Galassini, M. Crossey, P. Karayiannis, P. Georgiou, G. Atkinson, H. C. Thomas

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

This is the first double-blind controlled study of famciclovir, an oral antiviral agent, as potential therapy for chronic hepatitis B virus (HBV) carriers. A fall of more than 90% in HBV DNA levels was noted in six of 11 evaluable patients treated with a 10 day course of oral famciclovir. Further studies with more prolonged therapy are ongoing.

Original languageEnglish
Pages (from-to)211-215
Number of pages5
JournalJournal of Viral Hepatitis
Volume3
Issue number4
Publication statusPublished - Jul 1996

Keywords

  • Famciclovir
  • Hepatitis B virus
  • Nucleoside analogue

Fingerprint Dive into the research topics of 'A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection'. Together they form a unique fingerprint.

  • Cite this

    Main, J., Brown, J. L., Howells, C., Galassini, R., Crossey, M., Karayiannis, P., Georgiou, P., Atkinson, G., & Thomas, H. C. (1996). A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis, 3(4), 211-215.